SCHEMBL6561643

SCHEMBL6561643

CCCS(=O)(=O)NCC(C)(F)c1ccc(C(C)(F)CNS(=O)(=O)CCC)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 3/20 0.39
KIF11 P52732 1/20 0.38
GRIA4 P48058 2/20 0.35
CA1 P00915 5/20 0.35
CA2 P00918 5/20 0.35
CA9 Q16790 4/20 0.35
CA12 O43570 3/20 0.35
NR3C2 P08235 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
PTPN11 Q06124 1/20 0.34
NR3C1 P04150 1/20 0.34
CA5A P35218 1/20 0.33
KDM4E B2RXH2 2/20 0.33
HTT P42858 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5186074 0.92 HSD17B10 (0.36) ALDH1A1HSD17B10KIF11GRIA4CA1
SCHEMBL5186197 0.90 KIF11 (0.41) ALDH1A1KIF11GRIA4NR3C2CYP3A4
SCHEMBL5186075 0.90 HSD11B1 (0.42) ALDH1A1HSD17B10KDM4EHTT
SCHEMBL5186196 0.86 KIF11 (0.39) ALDH1A1HSD17B10KIF11GRIA4CYP3A4
SCHEMBL6155949 0.86 KIF11 (0.50) KIF11CA1CA2CA9CA12
SCHEMBL5186139 0.86 KIF11 (0.39) ALDH1A1HSD17B10KIF11GRIA4CYP3A4
SCHEMBL5186164 0.86 KIF11 (0.50) KIF11CA1CA2CA9CA12
SCHEMBL6155989 0.86 KIF11 (0.50) KIF11CA1CA2CA9CA12
SCHEMBL5186063 0.85 RXRA (0.40) ALDH1A1KIF11GRIA4
SCHEMBL5186056 0.85 KIF11 (0.44) HSD17B10KIF11GRIA4CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296945-B1 SULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2004-08-04 EP disclosed
US-6703425-B2 ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY 2004-03-09 US disclosed
US-20030229102-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229102-A1 Sulfonamide derivatives GRIN1, GRIN2A, SLC1A2 ALDH1A1 270/4885HSD17B10 946/4885KIF11 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.